Staidson Beijing Biopharma (300204) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Staidson Beijing Biopharma (300204) has a cash flow conversion efficiency ratio of -0.046x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-39.18 Million ≈ $-5.73 Million USD) by net assets (CN¥859.70 Million ≈ $125.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Staidson Beijing Biopharma balance sheet independence to measure how much of total assets are equity-financed.
Staidson Beijing Biopharma - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Staidson Beijing Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 300204 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Staidson Beijing Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Staidson Beijing Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing Hanrui Cobalt Co Ltd
SHE:300618
|
-0.086x |
|
Shanghai Liangxin Electrical Co Ltd
SHE:002706
|
0.042x |
|
dentalcorp Holdings Ltd
TO:DNTL
|
0.037x |
|
Concentrix Corporation
NASDAQ:CNXC
|
-0.030x |
|
Kennedy-Wilson Holdings Inc
NYSE:KW
|
-0.057x |
|
Hansol Chemica
KO:014680
|
0.061x |
|
Adriatic Metals Plc
AU:ADT
|
-0.451x |
|
Gaon Cable
KO:000500
|
0.025x |
Annual Cash Flow Conversion Efficiency for Staidson Beijing Biopharma (2007–2025)
The table below shows the annual cash flow conversion efficiency of Staidson Beijing Biopharma from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see 300204 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥806.72 Million ≈ $118.05 Million |
CN¥-125.68 Million ≈ $-18.39 Million |
-0.156x | -124.28% |
| 2024-12-31 | CN¥916.76 Million ≈ $134.15 Million |
CN¥-63.68 Million ≈ $-9.32 Million |
-0.069x | +68.83% |
| 2023-12-31 | CN¥1.02 Billion ≈ $149.36 Million |
CN¥-227.47 Million ≈ $-33.29 Million |
-0.223x | -71.83% |
| 2022-12-31 | CN¥1.35 Billion ≈ $198.11 Million |
CN¥-175.60 Million ≈ $-25.70 Million |
-0.130x | -24.10% |
| 2021-12-31 | CN¥1.55 Billion ≈ $226.92 Million |
CN¥-162.07 Million ≈ $-23.72 Million |
-0.105x | -44.78% |
| 2020-12-31 | CN¥1.59 Billion ≈ $232.30 Million |
CN¥-114.60 Million ≈ $-16.77 Million |
-0.072x | -366.21% |
| 2019-12-31 | CN¥1.64 Billion ≈ $239.29 Million |
CN¥44.34 Million ≈ $6.49 Million |
0.027x | -59.63% |
| 2018-12-31 | CN¥2.46 Billion ≈ $359.66 Million |
CN¥165.08 Million ≈ $24.16 Million |
0.067x | -45.77% |
| 2017-12-31 | CN¥2.21 Billion ≈ $323.30 Million |
CN¥273.64 Million ≈ $40.04 Million |
0.124x | +11.78% |
| 2016-12-31 | CN¥1.92 Billion ≈ $280.70 Million |
CN¥212.55 Million ≈ $31.10 Million |
0.111x | -19.24% |
| 2015-12-31 | CN¥1.68 Billion ≈ $246.39 Million |
CN¥231.01 Million ≈ $33.80 Million |
0.137x | +0.44% |
| 2014-12-31 | CN¥1.51 Billion ≈ $221.60 Million |
CN¥206.85 Million ≈ $30.27 Million |
0.137x | +61.17% |
| 2013-12-31 | CN¥1.31 Billion ≈ $192.28 Million |
CN¥111.36 Million ≈ $16.30 Million |
0.085x | +16.61% |
| 2012-12-31 | CN¥1.24 Billion ≈ $181.57 Million |
CN¥90.19 Million ≈ $13.20 Million |
0.073x | -7.94% |
| 2011-12-31 | CN¥1.10 Billion ≈ $161.27 Million |
CN¥87.01 Million ≈ $12.73 Million |
0.079x | -79.46% |
| 2010-12-31 | CN¥166.23 Million ≈ $24.32 Million |
CN¥63.91 Million ≈ $9.35 Million |
0.384x | +8.64% |
| 2009-12-31 | CN¥119.72 Million ≈ $17.52 Million |
CN¥42.37 Million ≈ $6.20 Million |
0.354x | +36.99% |
| 2008-12-31 | CN¥62.82 Million ≈ $9.19 Million |
CN¥16.23 Million ≈ $2.37 Million |
0.258x | +61.81% |
| 2007-12-31 | CN¥33.87 Million ≈ $4.96 Million |
CN¥5.41 Million ≈ $791.30K |
0.160x | -- |
About Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mou… Read more